Investment Rating - The report maintains an "Overweight" rating for the company [6][4]. Core Views - Despite a significant drop in vitamin prices in Q2 2025, the company's performance remains strong, driven by favorable product dynamics in methionine and steady growth in new materials and flavoring businesses [1][3]. - The increase in net profit for the first half of 2025 is primarily attributed to the robust market for vitamins A and E, with prices rising by 10% and 77% year-on-year, respectively [2]. - The company is expected to continue its growth trajectory in emerging fields such as animal nutrition, human nutrition, and high-end materials, with a positive outlook for future performance [3]. Summary by Sections Financial Performance - In H1 2025, the company achieved revenue of 11.1 billion RMB, a year-on-year increase of 13%, and a net profit of 3.6 billion RMB, up 63% year-on-year [1]. - Q2 2025 revenue was 5.7 billion RMB, reflecting a 6% year-on-year increase and a 4% quarter-on-quarter increase, with net profit of 1.7 billion RMB, up 29% year-on-year but down 8% quarter-on-quarter [1]. Segment Performance - The nutrition business generated revenue of 7.2 billion RMB in H1 2025, a 7.8% increase year-on-year, with a gross margin improvement of 11.9 percentage points to 47.8% [2]. - The flavoring business continued to grow, achieving revenue of 2.1 billion RMB, a 9.4% year-on-year increase, with a gross margin increase of 4.3 percentage points to 54% [2]. - The new materials segment reported revenue of 1.04 billion RMB, a significant year-on-year increase of 44% [2]. Profitability and Valuation - The report forecasts net profits for 2025-2027 to be 6.6 billion, 7.2 billion, and 8.0 billion RMB, respectively, with corresponding EPS of 2.14, 2.34, and 2.61 RMB [4]. - The target price has been adjusted to 27.82 RMB, based on a 13x PE ratio for 2025, reflecting an increase from the previous target of 23.65 RMB [4].